Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Size: px
Start display at page:

Download "Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver"

Transcription

1 Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

2 Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity Stereotactic Body Radiation Therapy - Extensive RT Oligometastatic

3 Intergroup Trial 0096 LSCLC 45 Gy QD or BID R a n d o m i z e 417 pts 45 Gy 25 fx 5 wks QD PE PE PE PE 45 Gy 30 fx 3 wks BID PCI PE PE PE PE PE: q 21 days Cisplatin 60 mg/m 2 day 1 Etoposide 120 mg/m 2 d 1,2,3 PCI: 25 Gy (2.5 Gy qd) Turrisi A et al, NEJM 340:265-71, 1999

4 Thoracic Radiotherapy Gross tumor, bilateral mediastinum, unilateral hilum No supraclavicular radiation Margin of 1 to 1.5 cm No CT simulation required No field reductions Turrisi A et al, NEJM 340:265-71, 1999

5 Intergroup Trial 0096 LSCLC 45 Gy QD or BID

6 Intergroup Trial 0096 LSCLC 45 Gy QD or BID 45 Gy QD 45 Gy BID Median survival 19 m 23 m 5-yr survival 16% 26% p=0.04 Local failure 52% 36% p=0.06 Simultaneous local/distant failure 23% 6% p=0.01 Turrisi A et al, NEJM 340:265-71, 1999

7 Intergroup Trial 0096 LSCLC 45 Gy QD or BID Landmark study but still controversy and questions Dose/fractionation of radiation therapy? Timing of starting radiation? Target to irradiate? Why would local treatment not affect local control but affect distant relapse?

8 CALGB 30610/ RTOG 0538 Eligibility LSCLC No contralateral hilar or supraclav N ECOG PS 0-2 Stratification ECOG 0 vs. 1-2 Weight loss Gender 3D vs. IMRT Accrual goal R A N D O M I Z E Arm A: Standard Cisplatin/Etoposide x 4 + Concurrent 45 Gy BID Arm B: Cisplatin/Etoposide x 4 + Concurrent 61.2 Gy QD/BID Arm C: Cisplatin/Etoposide x 4 + Concurrent 70 Gy QD 190 patients as of July 2011

9 CONVERT (EORTC/NCIC) Accrual goal 532 Eligibility LSCLC FEV1/KCO limits V20 < 35% Reasonable RT port ECOG PS 0-2 Stratification ECOG PS 0-1 vs 2 Center Na, Alk phos, LDH 242 accrued as of July 2011 R A N D O M I Z E Arm A: Control Cisplatin/Etoposide x 4-6 cycles Concurrent 45 Gy BID 3 wks Arm B: Experimental Cisplatin/Etoposide x 4-6 cycles Concurrent 66 Gy QD 33 fx

10 Same question but several differences CALGB/RTOG CONVERT Timing of RT Cycle 1 or 2 Cycle 2 Elective nodal RT Ipsilateral hilum No PFT limits No Yes Normal lung RT limits No Yes (V20 < 35%)

11 Timing of Thoracic Irradiation in LSCLC Thoracic radiation 40 Gy in 15fx Murray N et al, JCO 1993;11(2):336-44

12 Early Late 3 yr PFS 26% 19% P=0.036 Median survival 21.2 m 16 m P=0.008 Murray N et al, JCO 1993;11(2):336-44

13 Early vs Late Thoracic Radiation Sites of Failure No significant difference in thoracic recurrence: 50-60% recurrence at 2-3 yrs Significant difference in incidence of brain metastases Murray N et al, JCO 1993;11(2):336-44

14 Thoracic Radiation in LSCLC Meta-analysis 14% reduction in risk of death (p=.001) 5.4% (+/- 1.4%) absolute increase in 3 yr survival No significant difference if - Early or late thoracic radiation (< 60 days) - Sequential vs concurrent/alternating chemoradiation - Young (<55 yrs) vs old (>70 yrs) Pignon JP et al, NEJM 1992

15 Meta-Analysis of Timing of Chest Individual patient data RT in LSCLC Randomized trials ( ) of chemort for LSCLC comparing early (before day 49) versus late RT short versus longer duration Primary endpoint was overall survival Secondary endpoints PFS, acute > gr 3 toxicities, chemotherapy compliance ( different if compliance between arms > 10%) De Ruysscher D et al, Abst M019.03, WCLC 2011

16 Meta-Analysis of Timing of Chest RT in LSCLC 9 trials with 2,304 patients Results OS HR early vs late = 1.00 (p=0.92) PFS HR early vs late = 0.93 (p=.14) Toxicity early > late (anemia, esophagus, cardiac) CT compliance: if similar early better than late De Ruysscher D et al, Abst M019.03, WCLC 2011

17 Meta-Analysis of Timing of Chest RT in LSCLC De Ruysscher D et al, Abst M019.03, WCLC 2011

18 Meta-Analysis of Timing of Chest RT in LSCLC Conclusions: Differences in CT compliance between arms mostly explains heterogeneity in outcome If CT compliance similar between the arms, then early RT associated with improved 5-yr survival De Ruysscher D et al, Abst M019.03, WCLC 2011

19 If you knew the correct dose and time What to treat?

20 Radiation fields prior to 2010 CALGB/RTOG Gross disease Ipsilateral hilum Precarinal Bilateral paratracheal Subcarinal Aortopulmonary + para-aoritic if L sided CONVERT Gross disease

21 Current Radiation Fields CALGB/RTOG Gross disease Ipsilateral hilum Precarinal Bilateral paratracheal Subcarinal Aortopulmonary + para-aoritic if L sided CONVERT Gross disease

22 Amin N et al. JTO 2011 (in press)

23 Chemotherapy often leads to GTV reduction and risk of RP Amin N et al. JTO 2011 (in press)

24 Pre-Chemo Post-Chemo V20 decreased from 71 to 36% NTCP decreased from 44 to 16% Green 45 Gy Red 49.5 Gy Brown 22.5 Gy Amin N et al. JTO 2011 (in press)

25 Small Cell Toxicity Pneumonitis/Pulmonary Study N % > Gr 3 Ettinger D et al, JCO 2005 RTOG Gy BID + CEP Turrissi A et al, NEJM 1999 Int 45 Gy BID vs. 45 Gy QD Hanna N et al, Lung Cancer Gy QD + VIP Schild SE et al, JCO Gy BID split Le Q et al, JCO Gy QD + CP + tirapazamine 55 9% 417 2% 53 9% % 68 2%

26 Correlation of normal lung RT and Radiation Pneumonitis > Gr patients SCLC Sequential chemort 50 Gy standard fx 13% rate of symptomatic pneumonitis (needing drugs or hospitalization) Roeder F et al, Strahlenther Onkol 2010;186(3):149-56

27 Correlation of normal lung RT and RP > Gr 2 Nonsignificant factors V40 V10, 20, MLD V30 V20 V10 Age Gender Performance status Smoking history Tumor location FEV1 Roeder F et al, Strahlenther Onkol 2010;186(3):149-56

28 Prophylactic Cranial Irradiation (PCI) 5.4% Absolute improved survival at 3 yrs Auperin A et al, NEJM 1999;341:

29 PCI EORTC /RTOG 0212: Phase II/III study of PCI in LSCLC Stratify Age 1. <60 2. >60 Interval from Initial Tx 1. < >180 Accrual goal 720 R A N D O M I Z E Arm 1: 2.5 Gy qd x 10 fractions Total dose of 25 Gy Arm 2: 2.0 Gy qd x 18 Total dose 36 Gy Arm 3: 1.5 Gy bid x 24 Total dose 36 Gy Le Pechoux et al, Lancet 2009; 10:

30 P= Gy 36 Gy Le Pechoux et al, Lancet 2009; 10:

31 RTOG 0212: Impact of PCI on Chronic Neurotoxicity 264 evaluable patients No difference in QOL between doses Neurocognitive decline by 12 months 62% 25 Gy arm 85-90% 36 Gy arms Higher toxicity if age > 60 yrs Standard of care for PCI for LSCLC: 25 Gy in 10 fractions Wolfson A et al, IJROBP 2011;81(1):77-84 Le Péchoux C et al. Ann Oncol 2011;22:

32 Le Péchoux C et al. Ann Oncol 2011;22: The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please journals.permissions@oxfordjournals.org

33 Stereotactic Body Radiation Therapy (SBRT)

34 Stereotactic Body Radiation Therapy (SBRT) Breathing control is key Highly conformal Tight margins Pre-RT onboard imaging

35 Improved survival for surgery if N0 (SEER ) Schreiber D, et al. Cancer 2010;116:1350-7

36 SBRT for Stage I Medically Inoperable SCLC 6 patients biopsy proven clinical T1N0M0 between Plan was SBRT followed by platinum/etoposide followed by PCI SBRT dose varied (60 Gy/3 fx, 50 Gy/5 fx, 30 Gy in 1 fx) 100% local control, no regional node relapses Overall survival 63% at one year Disease free survival 75% at one year Videtic et al JTO 2011, 6(6): S1344

37 Role of Radiation Therapy in ESCLC RTOG cycles platin-based chemo Eligible ESCLC PS 0-2 No CNS mets 1-3 sites of mets CR or PR to chemo Stratify Response 1. CR 2. PR Number of Met Sites Accrual Goal 154 R A N D O M I Z E Arm 1: PCI 2.5 Gy in 10 fx Arm 2: PCI 2.5 Gy 10 fx + Consolidative RT to Locoregional and Residual Metastatic Disease 45 Gy in 15 fx or 40 Gy in 10 fx

38 Extensive SCLC: Implications for Oligometastatic RT 115 ESCLC patients % had disease confined to 1-3 sites (30% brain metastases) Only 57 patients received > 2 cycles chemo 39 primarily chemo with RT for palliation (1 PCI) 18 chemo and consolidative chest RT (7 PCI) Chest RT associated with improved local control and survival (33% vs 21% at 1 yr, p=.0459) PCI associated with improved 1 yr brain mets rate (60% vs 13%, p=.0003) Devisetty et al JTO 2011, 6(6): S1343

39 Summary of Update - Limited RT Dose being studied RT Timing?benefit to early RT Volume controversial PCI Neurotoxicity quantified SBRT possible but rare - Extensive RT Oligometastatic being studied

Current Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Current Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular

More information

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000

More information

Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer

Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung

More information

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March

More information

Place de la radiothérapie dans les CBPC métastatiques

Place de la radiothérapie dans les CBPC métastatiques Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens 1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days

More information

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly

More information

Locally advanced disease & challenges in management

Locally advanced disease & challenges in management Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden

More information

Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010

Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced

More information

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation

More information

Adjuvant Radiotherapy for completely resected NSCLC

Adjuvant Radiotherapy for completely resected NSCLC Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local

More information

NRG Oncology Lung Cancer Portfolio 2016

NRG Oncology Lung Cancer Portfolio 2016 NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III

More information

Combined modality treatment for N2 disease

Combined modality treatment for N2 disease Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical

More information

Protocol of Radiotherapy for Small Cell Lung Cancer

Protocol of Radiotherapy for Small Cell Lung Cancer 107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT

More information

Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY

Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo

More information

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history

More information

Adjuvant radiotherapy for completely resected early stage NSCLC

Adjuvant radiotherapy for completely resected early stage NSCLC Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique

More information

Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?

Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first? Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant

More information

Heterogeneity of N2 disease

Heterogeneity of N2 disease Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity

More information

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy

More information

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D. Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti

Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Brain Metastases Radiation Therapy of multiple brain metastases Is treatment appropriate? - Survival - QoL Brain Metastases

More information

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David

More information

Minesh Mehta, Northwestern University. Chicago, IL

Minesh Mehta, Northwestern University. Chicago, IL * Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics

More information

Treatment of LS (Stage I-III) SCLC

Treatment of LS (Stage I-III) SCLC Treatment of LS (Stage I-III) SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 9 th March 2018 @finn_corinne

More information

Pre- Versus Post-operative Radiotherapy

Pre- Versus Post-operative Radiotherapy Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology

More information

Debate 1 Are treatments for small cell lung cancer getting better? No:

Debate 1 Are treatments for small cell lung cancer getting better? No: Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University

More information

Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?

Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again? Editorial Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again? Cecile Le Pechoux 1, Angela Botticella 1, Antonin

More information

ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA

ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO

More information

1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL

1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL Current treatment practices for limited-stage small cell lung cancer: A survey of US radiation oncologists on the timing of thoracic radiotherapy with chemotherapy Matthew J. Farrell 1, Jehan Yahya 1,

More information

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer

More information

THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,

THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:

More information

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to

More information

Standard care plan for Prophylactic Cranial Irradiation for Limited Stage (stage I-III) Small Cell Lung Cancer (25Gy in 10 fractions) References

Standard care plan for Prophylactic Cranial Irradiation for Limited Stage (stage I-III) Small Cell Lung Cancer (25Gy in 10 fractions) References CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Prophylactic Cranial Irradiation for Limited-stage Small Cell Lung Cancer (20Gy in 5 fractions) Clinical Guideline Standard Care

More information

Pulmonary function tests 3. Is patient potentially operable? Yes. Inoperable. Yes. Zubrod performance status

Pulmonary function tests 3. Is patient potentially operable? Yes. Inoperable. Yes. Zubrod performance status te: Consider Clinical Trials as treatment options for eligible patients. INITIAL EVALUATION Pathology consistent with SCLC History and physical Chest x-ray Laboratory studies to include hematological and

More information

Small Cell Lung Cancer (SCLC): Update in Therapy. Anne Traynor, MD March 1, 2010

Small Cell Lung Cancer (SCLC): Update in Therapy. Anne Traynor, MD March 1, 2010 Small Cell Lung Cancer (SCLC): Update in Therapy Anne Traynor, MD March 1, 2010 Small Cell Lung Cancer (SCLC) 12% of lung cancer Strongest epi link with smoking Very high growth fraction Propensity for

More information

Treatment of Stage I-III SCLC

Treatment of Stage I-III SCLC Treatment of Stage I-III SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 3 rd March 2017 @finn_corinne

More information

Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC

Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University

More information

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N

More information

Combining chemotherapy and radiotherapy of the chest

Combining chemotherapy and radiotherapy of the chest How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department

More information

Treatment of Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice

More information

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival

More information

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy

More information

Locally advanced head and neck cancer

Locally advanced head and neck cancer Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary

More information

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D. The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain

More information

ASTRO Andrew J. Hope, M.D.

ASTRO Andrew J. Hope, M.D. IGRT for lung cancer; does XRT dose escalation improve outcome? Jeffrey Bradley, M.D. Associate Professor Department of Radiation Oncology Washington University and The Alvin J. Siteman Comprehensive Cancer

More information

Hot topics in Radiation Oncology for the Primary Care Providers

Hot topics in Radiation Oncology for the Primary Care Providers Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease

More information

Lung. Jing Zeng, MD University of Washington.

Lung. Jing Zeng, MD University of Washington. Lung Jing Zeng, MD University of Washington jzeng13@uw.edu Disclosure Employer: University of Washington I have no conflicts of interest to disclose. Learning Objectives Understand workup and staging of

More information

17th ESO ESMO Masterclass in Clinical Oncology

17th ESO ESMO Masterclass in Clinical Oncology NSCLC Radiotherapy Prof Corinne Faivre-Finn Manchester Radiotherapy Related Research Group Manchester Lung Cancer Group The Christie, Manchester, UK 17 th ESO-ESMO Masterclass 25 th March 2018 Early stage

More information

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective

More information

Where are we with radiotherapy for biliary tract cancers?

Where are we with radiotherapy for biliary tract cancers? Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute

More information

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,

More information

Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12

Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12 Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.

More information

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage

More information

The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer

The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation

More information

Adjuvant Chemotherapy

Adjuvant Chemotherapy State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant

More information

Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation

Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation Original Article Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation Masakuni Sakaguchi 1, Toshiya Maebayashi 1, Takuya Aizawa 1, Naoya Ishibashi 1, Tsutomu

More information

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,

More information

Lung Cancer Radiotherapy

Lung Cancer Radiotherapy Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think

More information

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients

More information

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014 Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R

More information

Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC) te: Consider Clinical Trials as treatment options for eligible patients. INITIAL EVALUATION Small Cell Lung Cancer (SCLC) Page 1 of 8 STAGE FURTHER ASSESSMENT Pathology consistent with SCLC History and

More information

Introduction: Methods: Results: Conclusions: PATIENTS AND METHODS Key Words: 1770

Introduction: Methods: Results: Conclusions: PATIENTS AND METHODS Key Words: 1770 Original Article Utilization of Hyperfractionated Radiation in Small-Cell Lung Cancer and Its Impact on Survival David Schreiber, MD,* Andrew T. Wong, MD,* David Schwartz, MD,* and Justin Rineer, MD Introduction:

More information

RESEARCH ARTICLE. Evrim Bayman 1 *, Durmus Etiz 1, Melek Akcay 1, Guntulu Ak 2. Abstract. Introduction

RESEARCH ARTICLE. Evrim Bayman 1 *, Durmus Etiz 1, Melek Akcay 1, Guntulu Ak 2. Abstract. Introduction DOI:http://dx.doi.org/10.7314/APJCP.2014.15.15.6263 RESEARCH ARTICLE Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Recent Advances in Lung Cancer: Updates from ASCO 2016

Recent Advances in Lung Cancer: Updates from ASCO 2016 Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016

More information

Radiotherapy in NSCLC: What are the ESMO Guidelines?

Radiotherapy in NSCLC: What are the ESMO Guidelines? - The role of radiation in early stage - RT/CT for unresectable NSCLC - Brain metastasis - Oligometastatic disease Radiotherapy in NSCLC: What are the ESMO Guidelines? Jean-Yves DOUILLARD MD PhD Chief

More information

Non small cell Lung Cancer

Non small cell Lung Cancer Non small cell Lung Cancer The 13th refresher course for residents in radiation oncology Jiraporn Setakornnukul, M.D. Radiation oncology division, Radiology department Siriraj Hospital, Mahidol University

More information

Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99

Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality

More information

What is Next for Patients with Stage III Non-Small Cell Lung Cancer?

What is Next for Patients with Stage III Non-Small Cell Lung Cancer? What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage

More information

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.

More information

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine ORIGINAL ARTICLE Tolerability of Accelerated Chest Irradiation and Impact on Survival of Prophylactic Cranial Irradiation in Patients with Limited-stage Small Cell Lung Cancer: Review of a Single Institution

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and

More information

Critical Clinical Updates

Critical Clinical Updates Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,

More information

RT +/- Surgery. Concurrent ChemoRT +/- Surgery

RT +/- Surgery. Concurrent ChemoRT +/- Surgery Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced

More information

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:

More information

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary

More information

Palliative radiotherapy in lung cancer

Palliative radiotherapy in lung cancer New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer

More information

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV

More information

Tecniche Radioterapiche U. Ricardi

Tecniche Radioterapiche U. Ricardi Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic

More information

SCLC: Developments in systemic treatment

SCLC: Developments in systemic treatment SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment

More information

Upper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m.

Upper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m. Upper Gastrointestinal Friday, March 2, 2018 2:00 p.m. 2:45 p.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response

More information

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line

More information

Small Cell Lung Cancer What we have now?

Small Cell Lung Cancer What we have now? Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,

More information